Benefits and Risks of Antiretroviral Therapy for Perinatal HIV Prevention

(N Engl J Med. 2016;375(18):1726–1737)Although triple-drug antiretroviral therapy (ART) has clear benefits for mothers and infants, studies have shown higher rates of adverse pregnancy outcomes with maternal ART than with regimens containing fewer antiretroviral agents. The Promoting Maternal and In...

Full description

Saved in:

Bibliographic Details
Published in:	Obstetric anesthesia digest Vol. 37; no. 3; pp. 154 - 155
Main Authors:	Fowler, M.G, Qin, M, Fiscus, S.A, Currier, J.S, Flynn, P.M, Chipato, T, McIntyre, J, Gnanashanmugam, D, Siberry, G.K, Coletti, A.S, Taha, T.E, Klingman, K.L, Martinson, F.E, Owor, M, Violari, A, Moodley, D, Theron, G.B, Bhosale, R, Bobat, R, Chi, B.H, Strehlau, R, Mlay, P, Loftis, A.J, Browning, R, Fenton, T, Purdue, L, Basar, M, Shapiro, D.E, Mofenson, L.M
Format:	Journal Article
Language:	English
Published:	Copyright Wolters Kluwer Health, Inc. All rights reserved 01-09-2017
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	(N Engl J Med. 2016;375(18):1726–1737)Although triple-drug antiretroviral therapy (ART) has clear benefits for mothers and infants, studies have shown higher rates of adverse pregnancy outcomes with maternal ART than with regimens containing fewer antiretroviral agents. The Promoting Maternal and Infant Survival Everywhere (PROMISE) trial thus compared the relative efficacy and safety of various open-label antiretroviral strategies and their effect on preventing mother-to-child transmission among asymptomatic HIV-infected pregnant women with high CD4 counts (at least 350 cells/mm).
ISSN:	0275-665X 1536-5395
DOI:	10.1097/01.aoa.0000521253.11653.d9